Akari Therapeutics Announces Positive Preliminary Results from First PNH Patient Treated With Coversin
2016-03-31 · AKARI Therapeutics · original akaritx.com ↗
NEW YORK and LONDON, March 31, 2016 Akari Therapeutics (NASDAQ: AKTX), an emerging growth, development-stage biopharmaceutical company, announced today preliminary results from the first paroxysmal nocturnal hemoglobinuria (PNH) patient treated with subcutaneously administered Coversin. The patient, diagnosed with PNH and resistant to eculizumab due to a polymorphism was started on Coversin under a clinical trial protocol approved by a EU national regulatory authority for treating PNH patients with eculizumab resistance. On Coversin therapy, administered subcutaneously, the patient demonstrated clinical and symptomatic improvement, complement inhibition (as measured by the CH50 assay) and a marked reduction of LDH (a marker of blood hemolysis). The patient will continue self-injection as per the protocol. Click here for full press release
The release as fetched from its publisher. akaritx.com ↗